Kiniksa Pharmaceuticals International (KNSA) vs Teva Pharmaceutical Industries (TEVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Teva Pharmaceutical Industries (TEVA) over the past year, gaining 104.5% versus a gain of 95.2%. Over five years, KNSA leads with a +580.9% price change compared with +304.8% for TEVA. Teva Pharmaceutical Industries is the larger company by market cap ($45.51 billion vs $6.03 billion), about 7.5 times the size, while Kiniksa Pharmaceuticals International is growing revenue faster (+60.1% vs +4.3%).
On valuation, Teva Pharmaceutical Industries trades at a lower forward P/E (12.6x vs 47.8x for Kiniksa Pharmaceuticals International). Kiniksa Pharmaceuticals International converts more of its revenue into profit, with a net margin of 8.7% versus 8.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KNSA | TEVA |
|---|---|---|
| Share price | $77.33 | $39.02 |
| Market cap | $6.03B | $45.51B |
| 1-day change | -0.81% | -0.41% |
| YTD return | +88.99% | +25.54% |
| 1-year return | +104.51% | +95.22% |
| 5-year return | +580.87% | +304.75% |
| P/E ratio (TTM) | 78.11 | 65.03 |
| Forward P/E | 47.81 | 12.63 |
| EPS (TTM) | $0.99 | $0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $677.56M | $17.26B |
| Revenue growth (YoY) | +60.09% | +4.32% |
| Net income (latest FY) | $59.01M | $1.41B |
| Gross margin | 88.54% | 51.79% |
| Operating margin | 11.40% | 12.50% |
| Net margin | 8.71% | 8.17% |
| 52-week high | $82.94 | $40.79 |
| 52-week low | $35.20 | $18.83 |
| Distance from 52-week high | -6.76% | -4.34% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +26.73% | +16.09% |
| Average volume | 578.96K | 5.29M |
| Shares outstanding | 48.29M | 1.17B |
| Employees | 366 | 31,173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Teva Pharmaceutical Industries is about 7.5 times larger than Kiniksa Pharmaceuticals International by market value ($45.51B vs $6.03B).
- Kiniksa Pharmaceuticals International grew revenue faster in its latest fiscal year (+60.09% vs +4.32%).
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
About Teva Pharmaceutical Industries
TEVA stock →Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Health Care · Biotechnology: Pharmaceutical Preparations · 31,173 employees
KNSA vs TEVA FAQ
Which is bigger, Kiniksa Pharmaceuticals International or Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries (TEVA) is larger, with a market capitalization of $45.51B compared with $6.03B for Kiniksa Pharmaceuticals International (KNSA).
Which stock has performed better over the past year, KNSA or TEVA?
KNSA returned +104.51% over the past 12 months, compared with +95.22% for TEVA (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, KNSA or TEVA?
TEVA has the lower trailing P/E at 65.0, versus 78.1 for KNSA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Kiniksa Pharmaceuticals International and Teva Pharmaceutical Industries in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.